Literature DB >> 29951514

Pioglitazone and cardiovascular risk in T2DM patients: is it good for all?

Muhammad Abdul-Ghani1, Amin Jayyous1, Nidal Asaad2, Sherif Helmy2, Jassim Al-Suwaidi2.   

Abstract

Entities:  

Year:  2018        PMID： 29951514      PMCID： PMC5994533          DOI： 10.21037/atm.2018.03.19

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  38 in total

1.  Glycemic control and prevention of retinopathy in Japanese NIDDM patients. A 10-year follow-up study.

Authors:  T Nakagami; R Kawahara; S Hori; Y Omori
Journal:  Diabetes Care       Date:  1997-04       Impact factor: 19.112

Review 2.  Thiazolidinediones in the treatment of insulin resistance and type II diabetes.

Authors:  A R Saltiel; J M Olefsky
Journal:  Diabetes       Date:  1996-12       Impact factor: 9.461

3.  Effects on the incidence of cardiovascular events of the addition of pioglitazone versus sulfonylureas in patients with type 2 diabetes inadequately controlled with metformin (TOSCA.IT): a randomised, multicentre trial.

Authors:  Olga Vaccaro; Maria Masulli; Antonio Nicolucci; Enzo Bonora; Stefano Del Prato; Aldo P Maggioni; Angela A Rivellese; Sebastiano Squatrito; Carlo B Giorda; Giorgio Sesti; Paolo Mocarelli; Giuseppe Lucisano; Michele Sacco; Stefano Signorini; Fabrizio Cappellini; Gabriele Perriello; Anna Carla Babini; Annunziata Lapolla; Giovanna Gregori; Carla Giordano; Laura Corsi; Raffaella Buzzetti; Gennaro Clemente; Graziano Di Cianni; Rossella Iannarelli; Renzo Cordera; Olga La Macchia; Chiara Zamboni; Cristiana Scaranna; Massimo Boemi; Ciro Iovine; Davide Lauro; Sergio Leotta; Elisabetta Dall'Aglio; Emanuela Cannarsa; Laura Tonutti; Giuseppe Pugliese; Antonio C Bossi; Roberto Anichini; Francesco Dotta; Antonino Di Benedetto; Giuseppe Citro; Daniela Antenucci; Lucia Ricci; Francesco Giorgino; Costanza Santini; Agostino Gnasso; Salvatore De Cosmo; Donatella Zavaroni; Monica Vedovato; Agostino Consoli; Maria Calabrese; Paolo di Bartolo; Paolo Fornengo; Gabriele Riccardi
Journal:  Lancet Diabetes Endocrinol       Date:  2017-09-13       Impact factor: 32.069

Review 4.  Reducing cardiovascular disease in patients with diabetes mellitus.

Authors:  Theodore Mazzone
Journal:  Curr Opin Cardiol       Date:  2005-07       Impact factor: 2.161

5.  Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial.

Authors:  Theodore Mazzone; Peter M Meyer; Steven B Feinstein; Michael H Davidson; George T Kondos; Ralph B D'Agostino; Alfonso Perez; Jean-Claude Provost; Steven M Haffner
Journal:  JAMA       Date:  2006-11-13       Impact factor: 56.272

Review 6.  Efficacy of lipid lowering drug treatment for diabetic and non-diabetic patients: meta-analysis of randomised controlled trials.

Authors:  João Costa; Margarida Borges; Cláudio David; António Vaz Carneiro
Journal:  BMJ       Date:  2006-04-03

7.  Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial.

Authors:  Helen M Colhoun; D John Betteridge; Paul N Durrington; Graham A Hitman; H Andrew W Neil; Shona J Livingstone; Margaret J Thomason; Michael I Mackness; Valentine Charlton-Menys; John H Fuller
Journal:  Lancet       Date:  2004 Aug 21-27       Impact factor: 79.321

8.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study.

Authors:  Y Ohkubo; H Kishikawa; E Araki; T Miyata; S Isami; S Motoyoshi; Y Kojima; N Furuyoshi; M Shichiri
Journal:  Diabetes Res Clin Pract       Date:  1995-05       Impact factor: 5.602

9.  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial.

Authors:  Steven E Nissen; Stephen J Nicholls; Kathy Wolski; Richard Nesto; Stuart Kupfer; Alfonso Perez; Horacio Jure; Robert De Larochellière; Cezar S Staniloae; Kreton Mavromatis; Jacqueline Saw; Bo Hu; A Michael Lincoff; E Murat Tuzcu
Journal:  JAMA       Date:  2008-03-31       Impact factor: 56.272

10.  Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.

Authors:  Ralph A Defronzo
Journal:  Diabetes       Date:  2009-04       Impact factor: 9.461
View more
  1 in total

Review 1.  Rethinking pioglitazone as a cardioprotective agent: a new perspective on an overlooked drug.

Authors:  Lorenzo Nesti; Domenico Tricò; Alessandro Mengozzi; Andrea Natali
Journal:  Cardiovasc Diabetol       Date:  2021-05-18       Impact factor: 9.951
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.